MA50424A - Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2 - Google Patents

Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2

Info

Publication number
MA50424A
MA50424A MA050424A MA50424A MA50424A MA 50424 A MA50424 A MA 50424A MA 050424 A MA050424 A MA 050424A MA 50424 A MA50424 A MA 50424A MA 50424 A MA50424 A MA 50424A
Authority
MA
Morocco
Prior art keywords
ccr6
methods
cxcr2 antagonist
treating generalized
pustulous
Prior art date
Application number
MA050424A
Other languages
English (en)
Inventor
James J Campbell
Karen Ebsworth
Antoni Krasinski
Venkat Reddy Mali
Jeffrey Mcmahon
Rajinder Singh
Ju Yang
Chao Yu
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA50424A publication Critical patent/MA50424A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA050424A 2018-01-08 2019-01-07 Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2 MA50424A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862614927P 2018-01-08 2018-01-08
US201862715503P 2018-08-07 2018-08-07

Publications (1)

Publication Number Publication Date
MA50424A true MA50424A (fr) 2020-08-26

Family

ID=67140280

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050424A MA50424A (fr) 2018-01-08 2019-01-07 Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2

Country Status (10)

Country Link
US (2) US11207294B2 (fr)
EP (1) EP3737366A4 (fr)
JP (1) JP7322036B2 (fr)
CN (1) CN111867579B (fr)
AU (1) AU2019205786B2 (fr)
CA (1) CA3087701A1 (fr)
IL (1) IL275839B2 (fr)
MA (1) MA50424A (fr)
TW (1) TWI821235B (fr)
WO (1) WO2019136370A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
US11207294B2 (en) 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
CN117018202A (zh) * 2019-07-08 2023-11-10 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
JP2023523300A (ja) 2020-04-30 2023-06-02 イドーシア ファーマシューティカルズ リミテッド Ｃｃｒ６受容体調節剤としてのアゼチジン－３－イルメタノール誘導体
WO2023057548A1 (fr) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
TW202325278A (zh) 2021-10-26 2023-07-01 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑
AR127486A1 (es) 2021-10-28 2024-01-31 Idorsia Pharmaceuticals Ltd Moduladores del receptor ccr6

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
AR033803A1 (es) 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
HUP0302382A3 (en) 2000-05-30 2004-09-28 Smithkline Beecham Corp Il-8 receptor antagonists and pharmaceutical compositions containing them
JP2004521106A (ja) 2001-01-16 2004-07-15 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
ATE419845T1 (de) 2001-01-16 2009-01-15 Smithkline Beecham Corp Il-8-rezeptor-antagonisten
US20030204085A1 (en) 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
KR20030090629A (ko) 2001-02-02 2003-11-28 쉐링 코포레이션 Ｃｘｃ 케모카인 수용체 길항제로서의 3,4-디-치환된사이클로부텐-1,2-디온
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1381590B1 (fr) 2001-04-16 2007-06-20 Schering Corporation Cyclobutène-1,2-diones disubstituées en positions 3,4 utilisées comme ligands de recepteurs de la chimiokine cxc
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
BR0308739A (pt) 2002-03-18 2005-01-11 Schering Corp Tratamentos em combinação para doenças mediadas por quimiocina
MXPA05011183A (es) 2003-04-18 2005-12-14 Schering Corp Sintesis de 2-hidroxi-n, n-dimetil- 3-[[2-[1(r) -(5-metil -2-furanil) propil]amino]-3, 4-dioxo-1 -ciclobuten-1 -il]amino] benzamida.
RU2388756C2 (ru) 2004-01-30 2010-05-10 Шеринг Корпорейшн Кристаллические полиморфные формы лиганда схс-хемокинового рецептора
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
JP2009542700A (ja) 2006-07-07 2009-12-03 シェーリング コーポレイション Ｃｘｃケモカイン受容体リガンドとしての３，４−ジ置換シクロブテン−１，２−ジオン
WO2008109177A2 (fr) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Inhibiteurs de métalloprotéase contenant une fraction hétérocyclique
US8183281B2 (en) 2007-06-06 2012-05-22 Novartis Ag CXC-chemokine receptor ligands
EP2178826B1 (fr) 2007-07-03 2017-05-17 Merck Sharp & Dohme Corp. Procédé et intermédiaires de synthèse de composés de 3,4-dioxo-1-cyclobutène 1,2-substitués
CA2694268A1 (fr) 2007-07-05 2009-01-08 Schering Corporation Procede pour obtenir une taille de cristaux controlee dans des composes 3,4-dioxo-1-cyclobutene 1,2-substitues
WO2009012375A2 (fr) 2007-07-19 2009-01-22 Wyeth Inhibiteurs de la squarate kinase
EP2215074B1 (fr) 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Composés d'isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations
MX2010006089A (es) 2007-12-04 2010-09-22 Schering Corp Metodos de tratamiento de enfermedad pulmonar obstructiva cronica.
WO2009156421A1 (fr) 2008-06-24 2009-12-30 Topotarget A/S Dérivés de l’acide squarique utilisés comme inhibiteurs du nicotinamide
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
JP2012505898A (ja) 2008-10-16 2012-03-08 シェーリング コーポレイション ピロリジン、ピペリジンおよびピペラジン誘導体ならびにそれらの使用方法
WO2010063802A1 (fr) 2008-12-05 2010-06-10 Novartis Ag Cyclobutène-1,2-diones 3,4-disubstituées en tant qu'antagonistes de récepteur cxcr2
WO2010091543A1 (fr) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Nouveaux dérivés d'hydrazinocyclobut-3-ène-1,2-dione comme antagonistes de cxcr2
WO2010131145A1 (fr) 2009-05-12 2010-11-18 Pfizer Limited Dérivés de cyclobutène-dione
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
EP3287438A1 (fr) 2011-09-02 2018-02-28 Novartis AG Sel de choline d'un composé cyclobutène-dione substitué anti-inflammatoire
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr) * 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
KR20200110476A (ko) * 2011-11-16 2020-09-23 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
JP2015522546A (ja) 2012-05-23 2015-08-06 ステマージ バイオテクノロジー エスエー ミトコンドリア電子伝達鎖の複合体（ｉｉｉ）の活性の阻害剤およびその使用
WO2015170430A1 (fr) * 2014-05-08 2015-11-12 学校法人慶應義塾 Agent inhibiteur des troubles inflammatoires subséquents à une dissection aortique
WO2016079049A1 (fr) 2014-11-17 2016-05-26 Medimmune Limited Combinaisons thérapeutiques et méthodes de traitement de la néoplasie
TWI724056B (zh) * 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
US11207294B2 (en) 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2

Also Published As

Publication number Publication date
IL275839B2 (en) 2024-02-01
AU2019205786A1 (en) 2020-08-06
CA3087701A1 (fr) 2019-07-11
WO2019136370A2 (fr) 2019-07-11
US20190209527A1 (en) 2019-07-11
IL275839B1 (en) 2023-10-01
WO2019136370A3 (fr) 2020-04-16
US20220280481A1 (en) 2022-09-08
EP3737366A2 (fr) 2020-11-18
CN111867579A (zh) 2020-10-30
TW201936600A (zh) 2019-09-16
AU2019205786B2 (en) 2023-12-14
EP3737366A4 (fr) 2022-07-27
US11207294B2 (en) 2021-12-28
JP2021510160A (ja) 2021-04-15
TWI821235B (zh) 2023-11-11
IL275839A (en) 2020-08-31
JP7322036B2 (ja) 2023-08-07
US11684606B2 (en) 2023-06-27
CN111867579B (zh) 2023-11-24

Similar Documents

Publication Publication Date Title
MA50424A (fr) Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2
MA43817A (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA47820A (fr) Traitement de la glycogénose de type iii
MA51525A (fr) Traitement de minéraux
EP4070336A4 (fr) Prédiction de la thrombo-embolie veineuse au moyen de modèles d'apprentissage automatique
MA56033A (fr) Méthodes de traitement de la sclérodermie généralisée
MA52738A (fr) Méthodes de traitement de l'arthrite psoriasique
DE112019004016T8 (de) Hydraulikkreislauf einer baumaschine
ES1225190Y (es) Conjunto de ducha
DK3208395T3 (da) Afløbsarrangement til bruse- eller badekar
JP1713919S (ja) 洗面台
JP1712851S (ja) 洗面台
JP1710612S (ja) 洗面台
TH2102005655S (th) ชุดฝักบัว
UA38358S (uk) Набір перових свердел
UA38528S (uk) Набір перових свердел
JP1721110S (ja) たらい
JP1718665S (ja) たらい
TH1902002339S (th) ชุดฝักบัว
TH2102000784S (th) อ่างล้างหน้า
UA44973S (uk) Лійка для душу
UA44974S (uk) Лійка для душу
TH2102005653S (th) ฝักบัว
TH2102005609S (th) ฝักบัว
ES1254511Y (es) Ducha